arrow
T

Thomas Lam

university of aberdeen
H指数:60
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting
2023-04-0121
OA
Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis
2022-05-0137
OAAI
Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium
2022-05-0121
OA
Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review
2022-05-0116
PRE
Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy
2022-04-0150
OA
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma

2021更新欧洲泌尿外科协会关于使用辅助帕博利珠单抗治疗肾细胞癌的指南

2022-02-0127
PRE
A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer
2021-11-0121
PREAI
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
2021-10-01115
PREAI
Shockwave Lithotripsy Versus Ureteroscopic Treatment as Therapeutic Interventions for Stones of the Ureter (TISU): A Multicentre Randomised Controlled Non-inferiority Trial

冲击波碎石术与输尿管镜治疗输尿管结石 (TISU): 一项多中心随机对照非劣效性试验

2021-07-0126
OAAI
A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research

与标准治疗方案相比,局部消融治疗临床局部前列腺癌的系统评价: 现有证据的局限性以及临床实践和进一步研究的建议

2021-06-0132
OA
The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium

组织学亚型对肾细胞癌患者术后复发的发生率,时间和模式的影响-RECUR Consortium的结果

2021-06-0138
PREAI
Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?

低危肾细胞癌患者在保留肾单位手术和根治性肾切除术后是否应该有不同的随访?

2021-04-266
OAAI
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naive Metastatic Clear-Cell Renal Cell Carcinoma
2021-03-01101
PREAI
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

前列腺癌eau-eanm-estron-esur-siog指南。II-2020部分更新: 复发性和转移性前列腺癌的治疗

2021-02-01716
PREAI
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

前列腺癌指南-2020更新。第1部分: 筛查、诊断和局部治疗

2021-02-011.9K
PREAI